Gene Therapy to Target MG7 for Oncology is under clinical development by Shanghai GeneChem and currently in Phase II for Metastatic Liver Cancer. According to GlobalData, Phase II drugs for Metastatic Liver Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Gene Therapy to Target MG7 for Oncology LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target MG7 for Oncology overview
Gene therapy is under development for the treatment of liver metastases expressing MG7 positively along with gastric cancer, and colorectal cancer. It is administered as intratumoral injection. It targets cells expressing carcinoembryonic antigen MG7. The therapeutic candidate is engineered MG7 specific CAR T-cells which are guided by ultrasound.
For a complete picture of Gene Therapy to Target MG7 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.